{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:58:27Z","timestamp":1791903507532,"version":"4.3.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"crossref","award":["CRG\/2021\/005484"],"award-info":[{"award-number":["CRG\/2021\/005484"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03349-9","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T07:01:49Z","timestamp":1786086109000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Survivin mRNA lipid nanoparticles and CTLA-4 inhibitor co-delivery activates anti-tumor cytotoxic T-lymphocytes for oral cancer immunotherapy"],"prefix":"10.1007","volume":"43","author":[{"given":"Vandana","family":"Krishna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srashti Gopal","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9686-9525","authenticated-orcid":false,"given":"Venkata Vamsi Krishna","family":"Venuganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"3349_CR1","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0140-6736(19)31146-8","volume":"394","author":"MA Peres","year":"2019","unstructured":"Peres MA, Macpherson D, Weyant LM, Daly RJ, Venturelli B, Mathur R, Listl MR, Celeste SK, Guarnizo-Herre\u00f1o R, Kearns CC, C., et al. Oral health 1 Oral diseases: a global public health challenge. Lancet. 2019;394:249\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(19)31146-8.","journal-title":"Lancet"},{"key":"3349_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/IJERPH17249160.","author":"S Abati","year":"2020","unstructured":"Abati S, Bramati C, Bondi S, Lissoni A, Trimarchi M. Oral Cancer and Precancer: A Narrative Review on the Relevance of Early Diagnosis. J Environ Res Public Heal. 2020. https:\/\/doi.org\/10.3390\/IJERPH17249160.","journal-title":"J. Environ. Res. Public Heal."},{"key":"3349_CR3","doi-asserted-by":"publisher","first-page":"7314","DOI":"10.2174\/0109298673309489240816063313","volume":"32","author":"Y Cheng","year":"2025","unstructured":"Cheng Y, Wang L, Zhang S, Jian W, Zeng B, Liang L, Deng Z. The Investigation of Nf\u03bab Inhibitors to Block Cell Proliferation in OSCC Cells Lines. Curr Med Chem. 2025;32:7314\u201326. https:\/\/doi.org\/10.2174\/0109298673309489240816063313.","journal-title":"Curr Med Chem"},{"key":"3349_CR4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/S40265-023-01835-2","volume":"833 83","author":"A Bhatia","year":"2023","unstructured":"Bhatia A, Burtness B. Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update. Drugs 2023. 2023;833 83:217\u201348. https:\/\/doi.org\/10.1007\/S40265-023-01835-2.","journal-title":"Drugs 2023"},{"key":"3349_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/S12935-021-02024-5","author":"G Cheng","year":"2021","unstructured":"Cheng G, Dong H, Yang C, Liu Y, Wu Y, Zhu L, Tong X, Wang S. A review on the advances and challenges of immunotherapy for head and neck cancer. Cancer Cell Int. 2021. https:\/\/doi.org\/10.1186\/S12935-021-02024-5.","journal-title":"Cancer Cell Int"},{"key":"3349_CR6","doi-asserted-by":"publisher","first-page":"1429265","DOI":"10.3389\/FPUBH.2024.1429265","volume":"12","author":"SM Iqbal","year":"2024","unstructured":"Iqbal SM, Rosen AM, Edwards D, Bolio A, Larson HJ, Servin M, Rudowitz M, Carfi A, Ceddia F. Opportunities and challenges to implementing mRNA-based vaccines and medicines: lessons from COVID-19. Front. Public Heal. 2024;12:1429265. https:\/\/doi.org\/10.3389\/FPUBH.2024.1429265.","journal-title":"Public Heal"},{"key":"3349_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-022-01007-w","volume":"71 7","author":"S Qin","year":"2022","unstructured":"Qin S, Tang X, Chen Y, Chen K, Fan N, Xiao W, Zheng Q, Li G, Teng Y, Wu M, et al. mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduct Target Ther 2022. 2022;71 7:1\u201335. https:\/\/doi.org\/10.1038\/s41392-022-01007-w.","journal-title":"Signal Transduct Target Ther 2022"},{"key":"3349_CR8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1021\/acs.accounts.1c00544","volume":"55","author":"Y Eygeris","year":"2022","unstructured":"Eygeris Y, Gupta M, Kim J, Sahay G. Chemistry of Lipid Nanoparticles for RNA Delivery. Acc. Chem Res. 2022;55:2\u201312.https:\/\/doi.org\/10.1021\/acs.accounts.1c00544","journal-title":"Chem Res"},{"key":"3349_CR9","doi-asserted-by":"publisher","DOI":"10.1021\/ACSNANOSCIENCEAU.2C00062","author":"X Xu","year":"2023","unstructured":"Xu X, Xia T. Recent Advances in Site-Specific Lipid Nanoparticles for mRNA Delivery. ACS Nanosci Au. 2023. https:\/\/doi.org\/10.1021\/ACSNANOSCIENCEAU.2C00062.","journal-title":"ACS Nanosci Au"},{"key":"3349_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41578-021-00358-0","author":"X Hou","year":"2021","unstructured":"Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021. https:\/\/doi.org\/10.1038\/s41578-021-00358-0.","journal-title":"Nat. Rev. Mater."},{"key":"3349_CR11","doi-asserted-by":"publisher","first-page":"120051","DOI":"10.1016\/J.IJPHARM.2020.120051","volume":"592","author":"S Maritim","year":"2021","unstructured":"Maritim S, Boulas P, Lin Y. Comprehensive analysis of liposome formulation parameters and their influence on encapsulation, stability and drug release in glibenclamide liposomes. Int J Pharm. 2021;592:120051. https:\/\/doi.org\/10.1016\/J.IJPHARM.2020.120051.","journal-title":"Int J Pharm"},{"key":"3349_CR12","doi-asserted-by":"publisher","DOI":"10.1021\/ACS.MOLPHARMACEUT.4C00276","author":"J Li","year":"2024","unstructured":"Li J, Zhang Y, Yang Y-G, Sun T. Advancing mRNA Therapeutics: The Role and Future of Nanoparticle Delivery Systems. Mol Pharm. 2024. https:\/\/doi.org\/10.1021\/ACS.MOLPHARMACEUT.4C00276.","journal-title":"Mol Pharm"},{"key":"3349_CR13","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.3390\/VACCINES12101148","volume":"12","author":"J Wang","year":"2024","unstructured":"Wang J, Ding Y, Chong K, Cui M, Cao Z, Tang C, Tian Z, Hu Y, Zhao Y, Jiang S. Recent Advances in Lipid Nanoparticles and Their Safety Concerns for mRNA Delivery. Vaccines. 2024;12:1148. https:\/\/doi.org\/10.3390\/VACCINES12101148.","journal-title":"Vaccines"},{"key":"3349_CR14","doi-asserted-by":"publisher","first-page":"4543","DOI":"10.1021\/ACS.NANOLETT.0C01386","volume":"20","author":"Y Eygeris","year":"2020","unstructured":"Eygeris Y, Patel S, Jozic A, Sahay G, Sahay G. Deconvoluting Lipid Nanoparticle Structure for Messenger RNA Delivery. Nano Lett. 2020;20:4543\u20139.https:\/\/doi.org\/10.1021\/ACS.NANOLETT.0C01386\/ASSET\/IMAGES\/LARGE\/NL0C01386_0005.JPEG.","journal-title":"Nano Lett"},{"key":"3349_CR15","doi-asserted-by":"publisher","first-page":"108198","DOI":"10.1016\/J.COMPBIOMED.2024.108198","volume":"171","author":"H Gong","year":"2024","unstructured":"Gong H, Liu Z, Yuan C, Luo Y, Chen Y, Zhang J, Cui Y, Zeng B, Liu J, Li H, et al. Identification of cuproptosis-related lncRNAs with the significance in prognosis and immunotherapy of oral squamous cell carcinoma. Comput Biol Med. 2024;171:108198. https:\/\/doi.org\/10.1016\/J.COMPBIOMED.2024.108198.","journal-title":"Comput Biol Med"},{"key":"3349_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-70861-x","author":"F Li","year":"2026","unstructured":"Li F, Han Y, Ou F, Deng L, Li H, Yu X, Yi Y, Ma R, Wu Z, You Z, et al. Spatial heterogeneity of MDSCs mediated by ANXA1-FPRs signaling drives immune suppression in OSCC progression. Nat Commun. 2026. https:\/\/doi.org\/10.1038\/s41467-026-70861-x.","journal-title":"Nat. Commun."},{"key":"3349_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/J.XCRM.2025.102399","author":"C Guo","year":"2025","unstructured":"Guo C, Gao T, Xue B, Zhang L, Wang S, Xiao R, et al. In situ extended immune activation instantly after tumor resection by oncolytic virus controls postoperative tumor recurrence. Cell Rep Med. 2025. https:\/\/doi.org\/10.1016\/J.XCRM.2025.102399.","journal-title":"Cell Rep Med"},{"key":"3349_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41368-020-0084-8","volume":"2020 121 12","author":"Z Mei","year":"2020","unstructured":"Mei Z, Huang J, Qiao B, Lam AK, yin. Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma. Int J Oral Sci. 2020;2020 121 12:1\u20139. https:\/\/doi.org\/10.1038\/s41368-020-0084-8.","journal-title":"Int J Oral Sci"},{"key":"3349_CR19","first-page":"175","volume":"497","author":"R Uppaluri","year":"2016","unstructured":"Uppaluri R. Uppaluri Lab Tissue Culture Protocols for MOC cell lines. lab Protoc. 2016;497:175\u20139.","journal-title":"lab Protoc"},{"key":"3349_CR20","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/S00262-016-1890-X","volume":"65","author":"RA Fenstermaker","year":"2016","unstructured":"Fenstermaker RA, Ciesielski MJ, Qiu J, Yang N, Frank CL, Lee KP, Mechtler LR, Belal A, Ahluwalia MS, Hutson AD. Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma. Cancer Immunol Immunother. 2016;65:1339\u201352. https:\/\/doi.org\/10.1007\/S00262-016-1890-X.","journal-title":"Cancer Immunol Immunother"},{"key":"3349_CR21","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1200\/JCO.22.00996","volume":"41","author":"MS Ahluwalia","year":"2023","unstructured":"Ahluwalia MS, Reardon DA, Abad AP, Curry WT, Wong ET, Figel SA, Mechtler LL, Peereboom DM, Hutson AD, Withers HG, et al. Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma. J Clin Oncol. 2023;41:1453\u201365. https:\/\/doi.org\/10.1200\/JCO.22.00996.","journal-title":"J Clin Oncol"},{"key":"3349_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6750-9-61\/FIGURES\/3","volume":"9","author":"O Edelheit","year":"2009","unstructured":"Edelheit O, Hanukoglu A, Hanukoglu I. Simple and efficient site-directed mutagenesis using two single-primer reactions in parallel to generate mutants for protein structure-function studies. BMC Biotechnol. 2009;9:1\u20138. https:\/\/doi.org\/10.1186\/1472-6750-9-61\/FIGURES\/3.","journal-title":"BMC Biotechnol"},{"key":"3349_CR23","doi-asserted-by":"publisher","first-page":"13737","DOI":"10.1074\/JBC.RA120.013805","volume":"295","author":"K Li","year":"2020","unstructured":"Li K, Liu T, Chen J, Ni H, Li W. Survivin in breast cancer\u2013derived exosomes activates fibroblasts by up-regulating SOD1, whose feedback promotes cancer proliferation and metastasis. J Biol Chem. 2020;295:13737. https:\/\/doi.org\/10.1074\/JBC.RA120.013805.","journal-title":"J Biol Chem"},{"key":"3349_CR24","doi-asserted-by":"publisher","first-page":"5587","DOI":"10.1007\/S00018-021-03864-0\/FIGURES\/7","volume":"78","author":"TR Reich","year":"2021","unstructured":"Reich TR, Schwarzenbach C, Vilar JB, Unger S, M\u00fchlh\u00e4usler F, Nikolova T, Poplawski A, Baymaz HI, Beli P, Christmann M, et al. Localization matters: nuclear-trapped Survivin sensitizes glioblastoma cells to temozolomide by elevating cellular senescence and impairing homologous recombination. Cell Mol Life Sci. 2021;78:5587\u2013604. https:\/\/doi.org\/10.1007\/S00018-021-03864-0\/FIGURES\/7.","journal-title":"Cell Mol Life Sci"},{"key":"3349_CR25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.5858\/2004-128-39-SABEIP","volume":"128","author":"P Kaur","year":"2004","unstructured":"Kaur P, Kallakury BSV, Sheehan CE, Fisher HAG, Kaufman Jr RP, Ross JS, Kaur P, Kallakury BSV, Sheehan CE, Fisher HAG, et al. Survivin and Bcl-2 Expression in Prostatic Adenocarcinomas. Arch Pathol Lab Med. 2004;128:39\u201343. https:\/\/doi.org\/10.5858\/2004-128-39-SABEIP.","journal-title":"Arch Pathol Lab Med"},{"key":"3349_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13046-019-1362-1","volume":"381 38","author":"F Li","year":"2019","unstructured":"Li F, Aljahdali I, Ling X. Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study? J Exp Clin Cancer Res 2019. 2019;381 38:1\u201322. https:\/\/doi.org\/10.1186\/S13046-019-1362-1.","journal-title":"J Exp Clin Cancer Res 2019"},{"key":"3349_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS22158035","author":"CG Kim","year":"2021","unstructured":"Kim CG, Sang YB, Lee JH, Chon HJ. Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/IJMS22158035.","journal-title":"Int. J. Mol. Sci"},{"key":"3349_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/J.TRANON.2021.101298","volume":"15","author":"X Lin","year":"2021","unstructured":"Lin X, Chen H, Xie Y, Zhou X, Wang Y, Zhou J, et al. Combination of CTLA-4 blockade with MUC1 mRNA nanovaccine induces enhanced anti-tumor CTL activity by modulating tumor microenvironment of triple negative breast cancer. Transl Oncol. 2021;15:101298. https:\/\/doi.org\/10.1016\/J.TRANON.2021.101298.","journal-title":"Transl Oncol"},{"key":"3349_CR29","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.3390\/PHARMACEUTICS14081572\/S1","volume":"14","author":"K Sasaki","year":"2022","unstructured":"Sasaki K, Sato Y, Okuda K, Iwakawa K, Harashima H. mRNA-Loaded Lipid Nanoparticles Targeting Dendritic Cells for Cancer Immunotherapy. Pharmaceutics. 2022;14:1572. https:\/\/doi.org\/10.3390\/PHARMACEUTICS14081572\/S1.","journal-title":"Pharmaceutics"},{"issue":"1","key":"3349_CR30","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1038\/s41598-024-52685-1","volume":"14","author":"GB Schober","year":"2024","unstructured":"Schober GB, Story S, Arya DP. A careful look at lipid nanoparticle characterization: analysis of benchmark formulations for encapsulation of RNA cargo size gradient. Sci Rep. 2024;14:2403. https:\/\/doi.org\/10.1038\/s41598-024-52685-1.","journal-title":"Sci Rep"},{"key":"3349_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/J.JCONREL.2025.114471","volume":"389","author":"S Jo","year":"2026","unstructured":"Jo S, Lee J, Park SI, Kim Y, Yoon S, Lee S, et al. A systemic evaluation of the effect of dsRNA contamination on mRNA vaccine expression and immunogenicity. J Control Release. 2026;389:114471. https:\/\/doi.org\/10.1016\/J.JCONREL.2025.114471.","journal-title":"J Control Release"},{"key":"3349_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/BTPR.70109","author":"K Zhao","year":"2026","unstructured":"Zhao K, Raffaele J, Holland DA, Feibelman K, Lengel K, Shanter J, et al. Enhancing mRNA vaccine production: optimization of in vitro transcription for improved yield and purity. Biotechnol Prog. 2026. https:\/\/doi.org\/10.1002\/BTPR.70109.","journal-title":"Biotechnol Prog"},{"key":"3349_CR33","doi-asserted-by":"publisher","unstructured":"Truong HQ, Kafle U, Nguyen CTG, Li Y, Meng F. (2026). Mechanistic insights into mRNA\u2013LNP interactions: role of ionizable lipid content in regulating mRNA intracellular release and translation. J. Nanobiotechnology 2026 241 24, 487. https:\/\/doi.org\/10.1186\/S12951-026-04383-5","DOI":"10.1186\/S12951-026-04383-5"},{"issue":"744","key":"3349_CR34","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/S00262-025-03992-7","volume":"2025","author":"CM Nguyen","year":"2025","unstructured":"Nguyen CM, Vu TT, Nguyen MN, Tran-Nguyen TS, Huynh CT, Ha QT, Nguyen HN, Tran LS. Neoantigen-based mRNA vaccine exhibits superior anti-tumor activity compared to synthetic long peptides in an in vivo lung carcinoma model. Cancer Immunol Immunother. 2025;2025(744):74\u2013145. https:\/\/doi.org\/10.1007\/S00262-025-03992-7.","journal-title":"Cancer Immunol Immunother"},{"key":"3349_CR35","doi-asserted-by":"publisher","unstructured":"Li T, Liu T, Zhu W, Xie S, Zhao Z, Feng B, Guo H, Yang R. (2021). Targeting MDSC for Immune-Checkpoint Blockade in Cancer Immunotherapy: Current Progress and New Prospects. Clin. Med. Insights Oncol. 15. https:\/\/doi.org\/10.1177\/11795549211035540\/ASSET\/ED6732D6-D927-4416-BB69-347ABB6419EE\/ASSETS\/IMAGES\/LARGE\/10.1177_11795549211035540-FIG3.JPG","DOI":"10.1177\/11795549211035540\/ASSET\/ED6732D6-D927-4416-BB69-347ABB6419EE\/ASSETS\/IMAGES\/LARGE\/10.1177_11795549211035540-FIG3.JPG"},{"key":"3349_CR36","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/BLOOD-2017-06-741033","volume":"131","author":"B Rowshanravan","year":"2018","unstructured":"Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood. 2018;131:58\u201367. https:\/\/doi.org\/10.1182\/BLOOD-2017-06-741033.","journal-title":"Blood"},{"key":"3349_CR37","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1200\/JCO.2019.37.15_SUPPL.2643","volume":"37","author":"G Cafri","year":"2019","unstructured":"Cafri G, Gartner JJ, Hopson K, Meehan RS, Zaks TZ, Robbins P, et al. Immunogenicity and tolerability of personalized mRNA vaccine mRNA-4650 encoding defined neoantigens expressed by the autologous cancer. J Clin Oncol. 2019;37:2643\u20132643. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_SUPPL.2643.","journal-title":"J Clin Oncol"},{"key":"3349_CR38","doi-asserted-by":"publisher","unstructured":"Parvin N, Joo SW, Mandal TK. (2024). Enhancing Vaccine Efficacy and Stability: A Review of the Utilization of Nanoparticles in mRNA Vaccines. Biomol. 2024, Vol. 14, Page 1036 14, 1036. https:\/\/doi.org\/10.3390\/BIOM14081036","DOI":"10.3390\/BIOM14081036"},{"key":"3349_CR39","doi-asserted-by":"publisher","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, Ladwa R, O\u2019byrne K, Kulasinghe A. (2022). Immune Checkpoint Inhibitors in Cancer Therapy. Curr. Oncol. 2022, Vol. 29, Pages 3044\u20133060 29, 3044\u20133060. https:\/\/doi.org\/10.3390\/CURRONCOL29050247","DOI":"10.3390\/CURRONCOL29050247"},{"key":"3349_CR40","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol 2020 2011. 2020;20:651\u201368. https:\/\/doi.org\/10.1038\/s41577-020-0306-5.","journal-title":"Nat Rev Immunol 2020 2011"},{"key":"3349_CR41","doi-asserted-by":"publisher","unstructured":"Liu Q, Liu Y, Li J, Huang S, Chen Z, Li J, Wang T, Zhou P, Huo J, Li D. A Precision-Engineered DC-Targeting mRNA-LNP Neoantigen Vaccine Elicits Stronger T Cell Responses and Exhibits Superior Tumor Control. Vaccines. 2026;14(239). https:\/\/doi.org\/10.3390\/VACCINES14030239\/S1.","DOI":"10.3390\/VACCINES14030239\/S1"},{"key":"3349_CR42","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024;403:632\u201344. https:\/\/doi.org\/10.1016\/S0140-6736(23)02268-7.","journal-title":"Lancet"},{"key":"3349_CR43","doi-asserted-by":"publisher","first-page":"ii52","DOI":"10.1093\/NEUONC\/NOAD137.169","volume":"25","author":"MS Ahluwalia","year":"2023","unstructured":"Ahluwalia MS, Ciesielski M, Abad A, Reardon D, Aiken R, Barbaro M, et al. P07.09.B A randomized phase 2B study of survivin vaccine SURVAXM plus adjuvant temozolomide for newly-diagnosed glioblastoma (SURVIVE). Neuro Oncol. 2023;25:ii52\u20133. https:\/\/doi.org\/10.1093\/NEUONC\/NOAD137.169.","journal-title":"Neuro Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03349-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03349-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03349-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T03:20:20Z","timestamp":1788924020000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-026-03349-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":43,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["3349"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03349-9","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"5 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors, have a patent application and\/or registration related to this work. The authors declare no financial interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"240"}}